DSM acquires postbiotics pioneer Adare Biome for €275 M

To realise the growth potential of postbiotics

Royal DSM, a global science-based leader in health, nutrition and bioscience, has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire French firm Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million.

Postbiotics is a rapidly emerging segment of the gut health market that is projected to grow strongly. Unlike the live bacteria in probiotics, postbiotics consist of inanimate microorganisms and/or their cellular components and metabolites that confer a health benefit to the host. A growing body of scientific evidence shows that postbiotics deliver comparable health benefits and are more stable so have a longer shelf-life and can be used in a wider range of applications and in new ingredient combinations.

Adare Biome’s origins date back to 1907 when French chemist Dr. Pierre Boucard launched Lactéol. This branded supplement for relieving gut upsets is now available over the counter in 35 countries and is one of the most scientifically well-documented microorganism-based therapeutics in the world in terms of efficacy and safety. DSM anticipates being able to rapidly extend the availability of Adare Biome’s Lactéol for people through its B2C unit, i-Health. 

Read Previous

Apis India expands portfolio with Hazelnut Chocolate Spread

Read Next

Nestlé unveils first ever soluble coffee

Leave a Reply